DGS Capital Management LLC Reduces Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

DGS Capital Management LLC lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 33.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 765 shares of the company’s stock after selling 380 shares during the quarter. DGS Capital Management LLC’s holdings in IDEXX Laboratories were worth $316,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. FSA Wealth Management LLC purchased a new stake in IDEXX Laboratories in the third quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. increased its position in shares of IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares in the last quarter. Mowery & Schoenfeld Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after purchasing an additional 60 shares during the last quarter. Ashton Thomas Securities LLC acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at about $37,000. Finally, Retirement Wealth Solutions LLC purchased a new position in IDEXX Laboratories during the 4th quarter worth approximately $31,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now owns 905 shares of the company’s stock, valued at $380,498.20. The trade was a 27.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.11% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on IDXX shares. Leerink Partners started coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective for the company. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. dropped their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Barclays decreased their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $523.86.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $435.33 on Friday. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The company has a 50-day moving average price of $423.74 and a 200 day moving average price of $456.35. The company has a market cap of $35.65 billion, a P/E ratio of 41.98, a PEG ratio of 3.63 and a beta of 1.36. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to analysts’ expectations of $980.32 million. During the same period last year, the firm earned $2.53 EPS. The company’s quarterly revenue was up 6.6% compared to the same quarter last year. Research analysts predict that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.